Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Net Income (2016 - 2025)

Enanta Pharmaceuticals' Net Income history spans 14 years, with the latest figure at -$11.9 million for Q4 2025.

  • For Q4 2025, Net Income rose 46.44% year-over-year to -$11.9 million; the TTM value through Dec 2025 reached -$71.5 million, up 33.06%, while the annual FY2025 figure was -$81.9 million, 30.59% up from the prior year.
  • Net Income reached -$11.9 million in Q4 2025 per ENTA's latest filing, up from -$18.7 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$11.9 million in Q4 2025 to a low of -$81.9 million in Q3 2021.
  • Average Net Income over 5 years is -$30.5 million, with a median of -$29.6 million recorded in 2021.
  • Peak YoY movement for Net Income: crashed 503.91% in 2021, then soared 67.85% in 2022.
  • A 5-year view of Net Income shows it stood at -$30.1 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then dropped by 15.25% to -$33.4 million in 2023, then skyrocketed by 33.28% to -$22.3 million in 2024, then skyrocketed by 46.44% to -$11.9 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Net Income are -$11.9 million (Q4 2025), -$18.7 million (Q3 2025), and -$18.3 million (Q2 2025).